ZA984268B - Method and composition for administering taxanes orally to human patients - Google Patents

Method and composition for administering taxanes orally to human patients

Info

Publication number
ZA984268B
ZA984268B ZA984268A ZA984268A ZA984268B ZA 984268 B ZA984268 B ZA 984268B ZA 984268 A ZA984268 A ZA 984268A ZA 984268 A ZA984268 A ZA 984268A ZA 984268 B ZA984268 B ZA 984268B
Authority
ZA
South Africa
Prior art keywords
composition
human patients
administering taxanes
taxanes orally
orally
Prior art date
Application number
ZA984268A
Other languages
English (en)
Inventor
Samuel Broder
Kenneth L Duchin
Sami Selim
Original Assignee
Baker Norton Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baker Norton Pharma filed Critical Baker Norton Pharma
Publication of ZA984268B publication Critical patent/ZA984268B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA984268A 1997-05-27 1998-05-20 Method and composition for administering taxanes orally to human patients ZA984268B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86351397A 1997-05-27 1997-05-27

Publications (1)

Publication Number Publication Date
ZA984268B true ZA984268B (en) 1999-06-23

Family

ID=25341241

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA984268A ZA984268B (en) 1997-05-27 1998-05-20 Method and composition for administering taxanes orally to human patients

Country Status (22)

Country Link
EP (1) EP0994706B1 (de)
JP (1) JP2002500667A (de)
KR (1) KR100615783B1 (de)
CN (2) CN1261275A (de)
AR (1) AR012731A1 (de)
AT (1) ATE308365T1 (de)
AU (1) AU7130098A (de)
BR (1) BR9809694A (de)
CA (1) CA2290446C (de)
CZ (1) CZ9904244A3 (de)
DE (1) DE69832173T2 (de)
DK (1) DK0994706T3 (de)
ES (1) ES2247690T3 (de)
HU (1) HUP0003546A3 (de)
IL (2) IL132992A0 (de)
NO (1) NO995812L (de)
PL (1) PL337064A1 (de)
RU (1) RU2205005C2 (de)
SK (1) SK157599A3 (de)
UA (1) UA74767C2 (de)
WO (1) WO1998053811A1 (de)
ZA (1) ZA984268B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6964946B1 (en) * 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
SK182599A3 (en) * 1997-06-20 2000-07-11 Baker Norton Pharma Soluble prodrugs of paclitaxel
GB9718903D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
AU4955200A (en) 1999-05-17 2000-12-05 Cancer Research Ventures Limited A method of improving bioavailability of orally administered drugs, a method of screening for enhancers of such bioavailability and novel pharmaceutical compositions for oral delivery of drugs
RU2236226C2 (ru) * 1999-06-18 2004-09-20 Бейкер Нортон Фармасьютикалз, Инк. Пероральные фармацевтические композиции, содержащие таксаны, и способы лечения с их применением
MXPA02004164A (es) * 1999-10-27 2002-10-17 Baker Norton Pharma Metodo y composiciones para administrar taxanos por via oral a pacientes humanos.
KR20020013174A (ko) * 2000-08-11 2002-02-20 민경윤 경구 흡수율이 낮은 약물의 흡수율을 증가시키기 위한경구용 조성물
US7115565B2 (en) 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
MXPA03006404A (es) * 2001-01-18 2004-12-02 Upjohn Co Composiciones quimioterapeuticas de microemulsion de paclitaxel con biodisponibilidad oral mejorada.
SI1372636T1 (sl) * 2001-02-28 2006-12-31 Bristol Myers Squibb Co Metronomsko odmerjanje taksanov za inhibiranje tumorske rasti
UY27185A1 (es) * 2001-02-28 2002-09-30 Bristol Myers Squibb Co Dosificación metronómica de taxanos
US7063977B2 (en) 2001-08-21 2006-06-20 Bristol-Myers Squibb Company Enzymatic resolution of t-butyl taxane derivatives
JP2008501708A (ja) * 2004-06-04 2008-01-24 スミスクライン ビーチャム （コーク） リミテッド がんの治療方法
GB0523659D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
AU2010256677A1 (en) * 2009-06-02 2012-01-12 Nikan Pharmaceuticals, Llc Antagonism of human formyl peptide receptor for treatment of disease
EP4059497A1 (de) * 2021-03-17 2022-09-21 Dompé farmaceutici S.p.a. C5ar1 inhibitoren zur behandlung von hypersensitivitätsreaktionen auf taxane
BR112023018826A2 (pt) * 2021-03-17 2024-03-12 Dompe Farm Spa Inibidores de c5ar1 para tratamento de reações de hipersensibilidade a taxanos

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411947A (en) * 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
DE69120430D1 (de) * 1990-12-18 1996-07-25 Wellcome Found Mittel zur verstaerkung der wirkung von antitumoralen mittel und zur widerstandsbekaempfung von vielfachdrogen
SG45403A1 (en) * 1991-01-11 1998-01-16 Glaxo Lab Sa Acridine derivatives
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
HU222496B1 (hu) * 1994-07-26 2003-07-28 Indena S.P.A. Félszintetikus taxánszármazékok, eljárás ezek előállítására, valamint ezeket tartalmazó gyógyászati készítmények
TW354293B (en) * 1995-06-06 1999-03-11 Bristol Myers Squibb Co Prodrugs of paclitaxel derivatives
US5916566A (en) * 1995-06-07 1999-06-29 Avmax, Inc. Use of benzoin gum to inhibit P-glycoprotein-mediated resistance of pharmaceutical compounds
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
WO1997027855A1 (en) * 1996-01-31 1997-08-07 Bristol-Myers Squibb Company A method of making pharmaceutically active taxanes orally bioavailable
CA2258556A1 (en) * 1996-06-17 1997-12-24 Julian Stanley Kroin Drug resistance and multidrug resistance modulators
GB9718903D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
EP1067908B9 (de) * 1998-04-01 2007-01-24 Jagotec Ag Taxan-mikroemulsionen

Also Published As

Publication number Publication date
UA74767C2 (en) 2006-02-15
HK1026637A1 (en) 2000-12-22
AR012731A1 (es) 2000-11-08
IL132992A0 (en) 2001-03-19
WO1998053811A1 (en) 1998-12-03
DE69832173T2 (de) 2006-08-03
JP2002500667A (ja) 2002-01-08
NO995812D0 (no) 1999-11-26
ATE308365T1 (de) 2005-11-15
HUP0003546A3 (en) 2002-12-28
CA2290446A1 (en) 1998-12-03
CA2290446C (en) 2008-01-29
RU2205005C2 (ru) 2003-05-27
KR20010013025A (ko) 2001-02-26
SK157599A3 (en) 2002-10-08
DK0994706T3 (da) 2006-03-06
DE69832173D1 (de) 2005-12-08
EP0994706A1 (de) 2000-04-26
HUP0003546A2 (hu) 2002-11-28
EP0994706A4 (de) 2001-05-16
IL132992A (en) 2006-08-20
CN1261275A (zh) 2000-07-26
BR9809694A (pt) 2000-10-03
ES2247690T3 (es) 2006-03-01
CN1550231A (zh) 2004-12-01
AU7130098A (en) 1998-12-30
CZ9904244A3 (cs) 2001-10-17
PL337064A1 (en) 2000-07-31
KR100615783B1 (ko) 2006-08-25
NO995812L (no) 2000-01-25
EP0994706B1 (de) 2005-11-02

Similar Documents

Publication Publication Date Title
PL341592A1 (en) Method of administering human aspb28 insulin
HUP0103357A3 (en) Halichondrin analogs and methods of their use and preparation
IL132992A0 (en) Method and compositions for administering taxanes orally to human patients
PL344246A1 (en) Novel pharmaceutical composition for use in emergency treatment and preparation method thereof
CY2007001I2 (el) Φαρμακευτικο σκευασμα για χρηση στη θεραπεια του διαβητη
AU1805499A (en) Method and apparatus for delivery of therapeutic agents to the heart
GB9808052D0 (en) Implants for administering substances and methods of producing implants
HUP0000808A3 (en) Pharmaceutical composition of fenofibrate and method for preparing same
HUP0300836A3 (en) Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
PL341566A1 (en) Oral composition of yttraconasole preparation and method of obtaining same
AUPO727097A0 (en) Method of treatment of hepatoma and pharmaceutical compositions for use therein
HUP0004096A3 (en) Aggregates of human insulin derivatives and pharmaceutical compositions comprising thereof
PL341230A1 (en) Solid dosage forms of ribavirin for oral administration and method of obtaining them
IL122405A (en) Methods for preparation of pharmaceutical composition for treatment of specific diseases using oils enriched in dha
IL149360A0 (en) Method and compositions for administering taxanes orally to human patients
EP1210075A4 (de) Zusammenstellungen und methoden zur veränderung des fettgehalts der haut
EP1181022A4 (de) Medizinische zusammensetzungen und verfahren zu deren herstellung
GB2343117B (en) Benzimidazole pharmaceutical composition and process of preparation
HUP9904317A3 (en) Use of 1-hydroxy-2-pyridones for producing pharmaceutical compositions suitable for the treatment of skin diseases
HUP0001526A3 (en) Use of nucleozides for producing pharmaceutical compositions for cytokine related treatments of disease and the pharmaceutical compositions
ZA964517B (en) Oral pharmaceutical composition of piperidinoalkanol compounds in solution form
EP1009433A4 (de) Therapeutische zusammensetzung und verfahren zur behandlung
AU784159C (en) Method and compositions for administering taxanes orally to human patients
HUP0203676A3 (en) Pharmaceutical composition and method for treatment of diabetes
HUP0300043A3 (en) Method and composition for the treatment of pain